U.S. FDA· FDA·· 2 hours agoScore92
FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery
In brief
On October 19, the FDA granted accelerated approval to Jemperli (dostarlimab-gxly) as a single agent for adults with previously untreated dMMR or MSI-H stage II or III locally advanced rectal cancer.
Source: U.S. FDA